Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Alzheimer's Disease

Free Subscription Articles published in JAMA Retrieve available abstracts of 68 articles: HTML format

Single Articles

September 2026
1. ANDERER S
   FDA Approves 2 New Alzheimer Disease Blood Tests.
   JAMA. 2026 Sep 18. doi: 10.1001/jama.2026.14721.
   PubMed    
   
   
   
2. BUCKLEY RF, Townsend DL, Birkenbihl CJ, Cuppels M, et al
   Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment.
   JAMA. 2026;336:950-959.
   PubMed     Abstract available
   
   
   July 2026
3. SCHINDLER SE, Wolk DA
   Predicting Risk of Cognitive Impairment With Alzheimer Disease Blood Biomarkers.
   JAMA. 2026 Jul 14. doi: 10.1001/jama.2026.13322.
   PubMed    
   
   
   
4. RABINOVICI GD, Grill JD
   Ceperognastat in Alzheimer Disease: Lessons From a Negative Clinical Trial.
   JAMA. 2026 Jul 13. doi: 10.1001/jama.2026.12323.
   PubMed    
   
   
   
5. FLEISHER AS, Munsie L, Mancini M, Cheng YJ, et al
   Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial.
   JAMA. 2026 Jul 13:e2612768. doi: 10.1001/jama.2026.12768.
   PubMed     Abstract available
   
   
   
6. BLAZHENETS G, Soleimani-Meigooni DN, Chiotis K, Allen IE, et al
   Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.
   JAMA. 2026 Jul 13:e2613116. doi: 10.1001/jama.2026.13116.
   PubMed     Abstract available
   
   
   
7. 
   Ceperognastat in Early Symptomatic Alzheimer Disease: Research Summary.
   JAMA. 2026 Jul 13:e2612911. doi: 10.1001/jama.2026.12911.
   PubMed    
   
   
   
8. BROWN CA, Robinson JL, Das SR, McGrew E, et al
   Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease.
   JAMA. 2026 Jul 12:e2613058. doi: 10.1001/jama.2026.13058.
   PubMed     Abstract available
   
   
   
9. LYNDON S, Behlke LM, Urizar JC, Daffner KR, et al
   Alzheimer Disease Biomarkers and Assisted Dying: When Diagnosis Becomes a Deadline.
   JAMA. 2026 Jul 9. doi: 10.1001/jama.2026.11317.
   PubMed    
   
   
   
10. RUBIN R
    First Alzheimer Disease Blood Test May Produce Many False-Positive Results, Study Finds.
    JAMA. 2026 Jul 2. doi: 10.1001/jama.2026.12326.
    PubMed    
    
    
    June 2026
11. HSIAO JK
    Stopping Alzheimer Disease: 50 Years of Progress.
    JAMA. 2026 Jun 22. doi: 10.1001/jama.2026.10969.
    PubMed    
    
    
    
12. CASALETTO KB, Dubal DB
    Female Clinical Resilience Despite Pathologic Risk in Alzheimer Disease.
    JAMA. 2026 Jun 10. doi: 10.1001/jama.2026.9351.
    PubMed    
    
    
    April 2026
13. KOSAKA M, Kami M
    Treatment of Early Symptomatic Alzheimer Disease With Valacyclovir.
    JAMA. 2026 Apr 2. doi: 10.1001/jama.2026.1102.
    PubMed    
    
    
    
14. DEVANAND DP, Wei R, Qian M
    Treatment of Early Symptomatic Alzheimer Disease With Valacyclovir-Reply.
    JAMA. 2026 Apr 2. doi: 10.1001/jama.2026.1105.
    PubMed    
    
    
    March 2026
15. RUBIN R
    Lithium for Alzheimer Disease-Pilot Study Sets the Stage for Larger Trials.
    JAMA. 2026 Mar 20. doi: 10.1001/jama.2026.3046.
    PubMed    
    
    
    
16. ANDERER S
    Alzheimer Disease Sex Differences May Be Tied to P-Tau217.
    JAMA. 2026 Mar 13. doi: 10.1001/jama.2026.1013.
    PubMed    
    
    
    January 2026
17. WHITSON HE, Fowler NR, Mielke MM
    Blood-Based Biomarkers for Alzheimer Disease: Preventing Unintended Consequences.
    JAMA. 2026 Jan 22. doi: 10.1001/jama.2025.26049.
    PubMed    
    
    
    December 2025
18. KNOPMAN DS
    Valacyclovir and Symptomatic Alzheimer Disease-No Evidence for Benefit.
    JAMA. 2025 Dec 17. doi: 10.1001/jama.2025.20795.
    PubMed    
    
    
    
19. 
    Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: Research Summary.
    JAMA. 2025 Dec 17:e2522830. doi: 10.1001/jama.2025.22830.
    PubMed    
    
    
    
20. DEVANAND DP, Wisniewski T, Razlighi Q, Qian M, et al
    Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial.
    JAMA. 2025 Dec 17:e2521738. doi: 10.1001/jama.2025.21738.
    PubMed     Abstract available
    
    
    
21. RUBIN R
    Alzheimer Disease Blood Test Cleared for Primary Care, but Questions Remain About Its Use.
    JAMA. 2025 Dec 5. doi: 10.1001/jama.2025.21573.
    PubMed    
    
    
    September 2025
22. ANDERER S
    Alzheimer Disease Exacerbated by Air Pollution, Study Suggests.
    JAMA. 2025 Sep 26. doi: 10.1001/jama.2025.13889.
    PubMed    
    
    
    
23. RUBIN R
    Trying to Unravel Why Alzheimer Disease Is More Common in Women.
    JAMA. 2025 Sep 26. doi: 10.1001/jama.2025.16269.
    PubMed    
    
    
    
24. ANDERER S
    First Antiamyloid Injectable Approved for Early Alzheimer Disease.
    JAMA. 2025 Sep 26. doi: 10.1001/jama.2025.13885.
    PubMed    
    
    
    August 2025
25. RUBIN R
    Treating Alzheimer Disease With Antiamyloid Therapies-The Real-World Experience Grows.
    JAMA. 2025 Aug 22. doi: 10.1001/jama.2025.14180.
    PubMed    
    
    
    
26. HUNT V
    An Alzheimer Biomarker Is Elevated in Newborns-Dementia Researchers Want to Know How They Clear It.
    JAMA. 2025 Aug 8. doi: 10.1001/jama.2025.13588.
    PubMed    
    
    
    July 2025
27. CHEN KY, Ross JS, Cohen AB, Karlawish J, et al
    Demographic Data Supporting FDA Authorization of AI Devices for Alzheimer Disease and Related Dementias.
    JAMA. 2025 Jul 30:e2512779. doi: 10.1001/jama.2025.12779.
    PubMed    
    
    
    June 2025
28. MOSCOSO A, Heeman F, Raghavan S, Costoya-Sanchez A, et al
    Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity.
    JAMA. 2025 Jun 16. doi: 10.1001/jama.2025.7817.
    PubMed     Abstract available
    
    
    
29. RUBIN R
    What to Know About the First FDA-Cleared Blood Test for Alzheimer Biomarkers.
    JAMA. 2025 Jun 13. doi: 10.1001/jama.2025.9013.
    PubMed    
    
    
    May 2025
30. ANDERER S
    Knowing Alzheimer Disease Risk May Reduce Lifestyle Change Motivation.
    JAMA. 2025 May 30. doi: 10.1001/jama.2025.7764.
    PubMed    
    
    
    January 2025
31. MINTZKER Y
    Blood Biomarkers to Detect Alzheimer Disease.
    JAMA. 2025 Jan 23. doi: 10.1001/jama.2024.25294.
    PubMed    
    
    
    
32. PALMQVIST S, Hansson O
    Blood Biomarkers to Detect Alzheimer Disease-Reply.
    JAMA. 2025 Jan 23. doi: 10.1001/jama.2024.25297.
    PubMed    
    
    
    September 2024
33. DEVERKA PA, Lin GA, Phillips KA
    Payer Coverage Considerations for Alzheimer Disease Blood-Based Biomarker Tests.
    JAMA. 2024 Sep 30. doi: 10.1001/jama.2024.19084.
    PubMed    
    
    
    August 2024
34. RUBIN R
    A Blood Test for Alzheimer Disease, Repurposing GLP-1s, and Wildfire Smoke-Highlights From the AAIC.
    JAMA. 2024 Aug 16. doi: 10.1001/jama.2024.13816.
    PubMed    
    
    
    July 2024
35. PALMQVIST S, Tideman P, Mattsson-Carlgren N, Schindler SE, et al
    Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.
    JAMA. 2024 Jul 28:e2413855. doi: 10.1001/jama.2024.13855.
    PubMed     Abstract available
    
    
    
36. SALLOWAY S, Rowe C, Burns JM
    Are Blood Tests for Alzheimer Disease Ready for Prime Time?
    JAMA. 2024 Jul 28. doi: 10.1001/jama.2024.12814.
    PubMed    
    
    
    
37. LU Y, Pike JR, Chen J, Walker KA, et al
    Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia.
    JAMA. 2024 Jul 28:e246619. doi: 10.1001/jama.2024.6619.
    PubMed     Abstract available
    
    
    
38. HARRIS E
    FDA Greenlights Second Alzheimer Drug, Donanemab.
    JAMA. 2024 Jul 26. doi: 10.1001/jama.2024.13386.
    PubMed    
    
    
    June 2024
39. RUBIN R
    A Neurologist Learned He Had Alzheimer Disease 8 Years Ago-Here's What He Wants People to Know.
    JAMA. 2024 Jun 28. doi: 10.1001/jama.2024.10805.
    PubMed    
    
    
    May 2024
40. HARRIS E
    Study: 2 APOE4 Copies May Indicate Genetic Form of Alzheimer Disease.
    JAMA. 2024 May 31. doi: 10.1001/jama.2024.9649.
    PubMed    
    
    
    
41. THAMBISETTY M, Howard R
    Conveying Risks of Harm in Alzheimer Disease by Amyloid Lowering.
    JAMA. 2024 May 6. doi: 10.1001/jama.2024.7548.
    PubMed    
    
    
    April 2024
42. RUBIN R
    Could GLP-1 Receptor Agonists like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?
    JAMA. 2024 Apr 19. doi: 10.1001/jama.2024.1017.
    PubMed    
    
    
    March 2024
43. KO D, Pascual-Leone A, Shah SJ
    Use of Lecanemab for Patients With Cardiovascular Disease: The Challenge of Uncertainty.
    JAMA. 2024 Mar 15. doi: 10.1001/jama.2024.2991.
    PubMed    
    
    
    
44. HARRIS E
    Biomarker Changes Can Begin 18 Years Before Alzheimer Disease Diagnosis.
    JAMA. 2024 Mar 6. doi: 10.1001/jama.2024.1568.
    PubMed    
    
    
    February 2024
45. HARRIS E
    Aducanumab Combined With Focused Brain Ultrasound More Effective.
    JAMA. 2024;331:466-467.
    PubMed    
    
    
    
46. HARRIS E
    Commercial Blood Test May Identify Alzheimer Disease Brain Pathology.
    JAMA. 2024 Feb 7. doi: 10.1001/jama.2024.0175.
    PubMed    
    
    
    December 2023
47. POMARA N, Imbimbo BP
    Use of Donanemab in Early Symptomatic Alzheimer Disease.
    JAMA. 2023;330:2304.
    PubMed    
    
    
    
48. EVANS CD, Sims JR
    Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.
    JAMA. 2023;330:2304-2305.
    PubMed    
    
    
    November 2023
49. RAFII MS, Fortea J
    Down Syndrome in a New Era for Alzheimer Disease.
    JAMA. 2023 Nov 22. doi: 10.1001/jama.2023.22924.
    PubMed    
    
    
    September 2023
50. RUBIN R
    Who Should-and Can-Get Lecanemab, the New Alzheimer Disease Drug?
    JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.14443.
    PubMed    
    
    
    
51. ODOUARD IC, Socal MP, Anderson GF
    Role of Registries in Medicare Coverage of New Alzheimer Disease Drugs.
    JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.17131.
    PubMed    
    
    
    
52. RUBIN R
    Consumers Can Now Buy a Blood Test to Evaluate Their Alzheimer Disease Risk, but Should They?
    JAMA. 2023 Sep 13. doi: 10.1001/jama.2023.17685.
    PubMed    
    
    
    August 2023
53. HARRIS E
    Study: Identifying Lewy Body Disease Before Symptoms.
    JAMA. 2023;330:686.
    PubMed    
    
    
    July 2023
54. HARRIS E
    MIND Diet No Better Than Control for Adults at Risk of Dementia.
    JAMA. 2023 Jul 26. doi: 10.1001/jama.2023.13134.
    PubMed    
    
    
    
55. HARRIS E
    Alzheimer Drug Lecanemab Gains Traditional FDA Approval.
    JAMA. 2023 Jul 19. doi: 10.1001/jama.2023.12548.
    PubMed    
    
    
    
56. SIMS JR, Zimmer JA, Evans CD, Lu M, et al
    Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
    JAMA. 2023 Jul 17:e2313239. doi: 10.1001/jama.2023.13239.
    PubMed     Abstract available
    
    
    
57. ROSENTHAL MB
    Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11702.
    PubMed    
    
    
    
58. MANLY JJ, Deters KD
    Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11704.
    PubMed    
    
    
    
59. RABINOVICI GD, La Joie R
    Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11703.
    PubMed    
    
    
    
60. WIDERA EW, Brangman SA, Chin NA
    Ushering in a New Era of Alzheimer Disease Therapy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11701.
    PubMed    
    
    
    
61. HARRIS E
    More Lean Muscle Might Reduce Alzheimer Disease Risk.
    JAMA. 2023 Jul 12. doi: 10.1001/jama.2023.12544.
    PubMed    
    
    
    June 2023
62. HARRIS E
    CMS Will Cover Alzheimer Drugs With Traditional FDA Approval.
    JAMA. 2023 Jun 14. doi: 10.1001/jama.2023.10400.
    PubMed    
    
    
    
63. HARRIS E
    Brain Cell Biomarker for Preclinical Alzheimer Disease Identified.
    JAMA. 2023 Jun 7. doi: 10.1001/jama.2023.9928.
    PubMed    
    
    
    May 2023
64. HARRIS E
    FDA Greenlights First Drug for Agitation Related to Alzheimer Disease.
    JAMA. 2023 May 24. doi: 10.1001/jama.2023.9153.
    PubMed    
    
    
    
65. MARCUS R
    New Alzheimer Disease Drugs, Long COVID and the Central Nervous System, and a Nasal Spray for Migraines-Highlights From the 2023 American Academy of Neurology Conference.
    JAMA. 2023 May 10. doi: 10.1001/jama.2023.4389.
    PubMed    
    
    
    March 2023
66. HARRIS E
    Blood Biomarker Helps Distinguish Vascular Dementia.
    JAMA. 2023;329:969.
    PubMed    
    
    
    February 2023
67. HARRIS E
    Healthful Lifestyle May Slow Memory Loss, Even for APOE Gene Carriers.
    JAMA. 2023;329:622.
    PubMed    
    
    
    October 2021
68. EMANUEL EJ
    A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
    JAMA. 2021;326:1367-1368.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum